Financial Guidance - Indivior PLC expects total net revenue for 2026 to be in the range of $1.125 billion to $1.195 billion, with SUBLOCADE® net revenue anticipated between $905 million and $945 million [1] - The company aims to grow SUBLOCADE net revenue by 11% at the midpoint of its guidance range, while raising adjusted EBITDA by 35% and adjusted EBITDA margin by 14 percentage points [2] Business Highlights - Indivior PLC was included in the S&P SmallCap 600® index effective December 22, 2025 [3] - The company received shareholder approval to change its domicile from the U.K. to the U.S., with the new U.S. parent company, Indivior Pharmaceuticals, Inc., expected to take effect on January 26, 2026 [3] - Indivior paid off an outstanding obligation of $295 million and concluded a legacy U.S. Department of Justice matter [3] Company Overview - Indivior PLC develops, manufactures, and sells buprenorphine-based prescription drugs for treating opioid dependence, with products including Suboxone Film, Suboxone Tablet, and Subutex Tablet [4] - The company's operations are divided into geographical segments: United States, Rest of World, and United Kingdom [4]